Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Morschhauser

Showing results (21-30 of 315) with videos related to

Pageof 32
Sort By:
Anti-Cancer Drugs|September 1, 2007
Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibodyDidier Decaudin, Raphaël Levy, François Lokiec, et al.
Fertility and Sterility|June 22, 2014
Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assayChristine Decanter, Maeliss Peigne, Audrey Mailliez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2018
Through the Glass CeilingHervé Tilly, Gilles Salles, Thierry J Molina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 13, 2009
Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphomaThomas Cazaentre, Franck Morschhauser, Maximilien Vermandel, et al.
Blood|May 4, 2018
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evilCharles Herbaux, Reid Merryman, Steven Devine, et al.
Leukemia & Lymphoma|February 27, 2020
Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline <sup>18</sup>F-FDG PET-CTGauthier Delaby, Marc-Antoine Hubaut, Franck Morschhauser, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 1, 2005
Testicular natural killer T-cell lymphomaCharles Ballereau, Xavier Leroy, Franck Morschhauser, et al.
Current Hematologic Malignancy Reports|June 23, 2012
Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?Rene-Olivier Casasnovas, Michel Meignan, Alina Berriolo-Riedinger, et al.
Leukemia & Lymphoma|January 10, 2025
gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profilesWill Harris, Yi Cao, Franck Morschhauser, et al.
Blood Reviews|July 19, 2022
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomasFranck Morschhauser, Gilles Salles, Connie Lee Batlevi, et al.
Pageof 32

Showing results (21-30 of 315) with videos related to

Sort By:
Pageof 32
Anti-Cancer Drugs|September 1, 2007
Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibodyDidier Decaudin, Raphaël Levy, François Lokiec, et al.
Fertility and Sterility|June 22, 2014
Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assayChristine Decanter, Maeliss Peigne, Audrey Mailliez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2018
Through the Glass CeilingHervé Tilly, Gilles Salles, Thierry J Molina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 13, 2009
Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphomaThomas Cazaentre, Franck Morschhauser, Maximilien Vermandel, et al.
Blood|May 4, 2018
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evilCharles Herbaux, Reid Merryman, Steven Devine, et al.
Leukemia & Lymphoma|February 27, 2020
Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline <sup>18</sup>F-FDG PET-CTGauthier Delaby, Marc-Antoine Hubaut, Franck Morschhauser, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 1, 2005
Testicular natural killer T-cell lymphomaCharles Ballereau, Xavier Leroy, Franck Morschhauser, et al.
Current Hematologic Malignancy Reports|June 23, 2012
Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?Rene-Olivier Casasnovas, Michel Meignan, Alina Berriolo-Riedinger, et al.
Leukemia & Lymphoma|January 10, 2025
gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profilesWill Harris, Yi Cao, Franck Morschhauser, et al.
Blood Reviews|July 19, 2022
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomasFranck Morschhauser, Gilles Salles, Connie Lee Batlevi, et al.
Pageof 32